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Abstract
Background: Infection with genital Chlamydia trachomatis (Ct) is the most common notifiable
sexually transmitted infection (STI) in Sweden. A mutated Chlamydia, nvCT, has contributed to the
increase. The occurrence of repeat infections is not investigated in Sweden. The current paper
presents the study protocol for the first Swedish clinical investigation of repeat Chlamydial
infection. The concern of the study is whether a Chlamydia infection at inclusion indicates an
increased risk for Chlamydia at follow-up after 6–8 months, gender-specific risk factors for and
clinical presentation of repeat infections.
Methods and design: Sesam City is a drop-in clinic in the city centre of Stockholm. Patients 20
years and older are admitted. During 2007, the clinic had 15 000 visits, 60% made by men. In
December 2007, a cohort study began, and data collection was finished in April 2009. A total of
2813 study participants aged 20–39 years were recruited. Data collection included an anonymous
self-administered paper-and-pen questionnaire on sexual behaviour, reproductive health and
history of Chlamydia, and condom use. Chlamydia tests were performed by self-sampled
specimens, analyzed by the ProbeTec (Becton Dickinson) method, Ct-positive specimens also
analyzed with a nvCT-specific method. Data from medical records were summarized in clinical
report forms. Patients positive for Chlamydia were retested 4 weeks after treatment. Contact
tracing covered sexual contacts during the last 12 months. At follow-up 6–8 months after inclusion,
Chlamydia tests were performed, and a new questionnaire and CRF completed.
Discussion: A STI-clinic-based prospective cohort study allowed us to survey 2813 adult patients.
The collected data will provide gender-specific information on the occurrence of and risk for
repeat Chlamydia infection, the occurrence of nvCT, and clinical data and information on sexual
behaviour and reproductive health, risk-taking and condom use.
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Background
Genital infection with Chlamydia trachomatis in Sweden
Genital infection with Chlamydia trachomatis is the most
common notifiable sexually transmissible infection in
Sweden, and included in the Act of Communicable Dis-
eases. Testing and treatment is free of charge. Contact trac-
ing is mandatory. National statistics are based on reports
from physicians and counsellors. Records are identified
with a code in order to protect the identity of the patient.
An increasing number of cases is reported to the national
surveillance system since the late 1990's, and statistics is
available at The Swedish Institute for Infectious Disease
Control [1]. In 1997, 13 905 cases were reported (157
cases per 100 000 population), and in 2006 32 555 cases
(360 per 100 000 population). More cases are reported
among females than males. The overall majority is young:
teenagers and adults < 30 years.
Changes in sexual behaviour contribute to the increase of
Ct [2]. In late 2006, a new variant of Chlamydia trachom-
atis (nvCT) was identified in Sweden [3]. The mutant has
a deletion in the cryptic plasmid, and escaped diagnostic
laboratory methods widely used in Sweden. When labora-
tories changed their methods to be able to identify nvCT,
a steep increase of reported cases occurred [4]. In 2007, 47
099 cases (513 per 100 000 population) were reported,
interpreted as a catch-up effect [5]. However, the increase
of Chlamydia cases continues also when nvCT is included
in testing systems used all over Sweden. For 2008 42 000
(454 cases per 100 000) were reported.
Risk factors for Chlamydia and repeat infections
Young age has since long been identified as the most
important risk factor for Chlamydial infection, and inter-
national guidelines recommend regular testing of women
aged <25 years old [6]. Furthermore, one previous episode
of Chlamydia has been found to be a risk factor for a
recurrent or new infection, often within a year, and for
both sexes. This has been shown in population-based as
well as in observational studies from STI clinics [7-15].
The reason for a positive test at follow-up may depend on
when testing is performed, as the reason may be a persist-
ent infection, a reinfection by untreated partner/partners,
or a new infection. Repeat testing of Chlamydia-infected
persons is recommended at different times: as a test of
cure, after 3 months, annually, and according to the per-
ceived risk of the patient.
The occurrence of repeat Chlamydial infection cannot eas-
ily be calculated on the basis of national statistics due to
anonymization of records. However, a retrospective study
of the anonymized STD registry was performed by Bengts-
son in 2004 [16]. By use of Chlamydia statistics from
1997 to 2000, and maximum likelihood theory, an esti-
mation of the risk for recurrent diagnoses was performed.
The risk ratios vary between the sexes and different age
groups, but increase during the investigated period. For
1999, 18% of teenage girls with Chlamydia were esti-
mated to have a new infection within 2 years, compared
with 10% of of teenage boys, and 8% of both sexes aged
25–29 years. Consequently, rescreening of individuals
who have tested positive for Chlamydia is recommended,
but further investigations and clinical studies have not
been performed.
Repeat infections and sequelae in women
The impact of repeat infections is the risk for further
spread, but also an increased risk for Chlamydia-related
complications. Women are most at risk, pelvic inflamma-
tory disease (PID), ectopic pregnancy and infertility are
well-known complications to Chlamydial infections. The
risk for infertility has been shown to increase with repeat
episodes of salpingitis. Today, the excess of female infer-
tility after Chlamydial infections is questioned, and a few
investigators have recently critically reviewed the basis of
current knowledge [17-20]. It is a fact that the natural his-
tory of infection is not completely understood, and it is a
paradox that parallel to the increase of cases fewer compli-
cations are observed by the clinicians. However, "silent
salpingitis" is a clinical entity, and ectopic pregnancy is
related to Chlamydia infections shown in register-based
investigations from Sweden and Norway [21-23].
Objectives and rationale for the study
The occurrence of repeat Chlamydial infection in Sweden
is still to be investigated, as well as the clinical presenta-
tion of repeat infections. The challenge for STI-clinics and
low-threshold clinics is awareness of symptoms and signs
that indicate risk for complicated Chlamydial infection,
and to treat it accordingly. The aim of the present prospec-
tive cohort study is to investigate the occurrence of repeat
infections among the visitors to the Sesam City Clinic.
The four study questions are: after 6 – 8 months follow-
up, do patients treated for Chlamydial infection have a
higher rate of recurrency/repeat infection, than subjects
testing negative for Chlamydia at inclusion? Is there a dif-
ference in clinical presentation between initial and repeat
infections? Is there a difference in repeat infections in
mutant (nvCT) and non-mutant (wCT) chlamydial infec-
tions? Can behavioural risk factors for repeat Chlamydial
infection be identified?
The data collected will provide information for the plan-
ning of appropriate clinical care for STI-clinic visitors,
with focus on Chlamydia and indications for retesting.
Methods and design
The study is designed as a prospective cohort study with
initial data collection at inclusion, and follow-up record-
ing 6–8 months later. Inclusion criteria are age 20–39BMC Public Health 2009, 9:198 http://www.biomedcentral.com/1471-2458/9/198
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years, knowledge of Swedish sufficient to answer the study
questionnaires, and a sample for Chlamydia. The objec-
tive is both to compare Chlamydia infection status of the
participants at inclusion and at the follow-up visit, and to
investigate potential risk factors for infection and reinfec-
tion.
Setting
In 2006, the Sesam City project began in order to facilitate
Chlamydia screening for young adults. Sesam City is now
a drop-in STI clinic for adults aged from 20 years and
older in the city centre of Stockholm, run by the Dept. of
Obstetrics and Gynaecology at the Karolinska University
Hospital. It is open five days a week, in the afternoon and
early evening, and is the only hospital-run clinic of its
kind in the capital. The staff consists of specially trained
nurses and midwives, counsellors and a part-time gynae-
cologist. Venereologists are recruited from the Dept. of
Dermatovenereology from the Karolinska University Hos-
pital.
In 2006, approx. 15 000 visits were made, 60% by men.
The majority of all patients were tested for Chlamydia. Of
all patients, 10% tested positive. In a pilot project from
the clinic in early 2007, the new variant of Chlamydia,
nvCT, represented 23% of 115 consecutively diagnosed
Chlamydia cases [24].
The inclusion period with the recruitment of study partic-
ipants started December 12 2007 and continued until
June 2 2008. The follow-up period for data collection
took place between August 22 2008 to April 30 2009. The
data collection upon inclusion consisted of self adminis-
tered paper-and-pen questionnaires, laboratory results for
Chlamydia and separately for nvCT, the clinical data from
the medical records summarized into clinical report forms
(CRFs), and results of the contact tracing All Chlamydia
positive patients were scheduled for a test of cure 4–6
weeks after finishing their treatment, and answered a one-
page questionnaire at that time. At follow-up a new ques-
tionnaire was completed, a lab test for Chlamydia per-
formed, and a CRF completed.
Participants
All visitors to the clinic were consecutively invited to par-
ticipate in the study according to the inclusion criteria.
Information was provided at the reception desk by one of
the clinic's specially trained nurses. Visitors who agreed to
participate in the study were asked to answer the question-
naire, and to leave a sample for Chlamydia testing.
Patients with genital symptoms were examined by a phy-
sician. All symptom-free patients were seen by a nurse. Six
to eight months after the initial visit, all participants were
invited to return for the follow-up visit. Due to the sum-
mer holiday period in Sweden during July and August, the
follow-up period started in late August.
When patients arrived at Sesam City, they were met by a
nurse at the clinic's reception desk. The desk is separated
by a glass door from the common waiting room. Patients
who would consider participation in the study received an
envelope, marked with a study number, and a ballpoint
pen. The envelope contained information on the study to
be kept by the respondent, a consent form to sign, and a
contact form with the patient's full ID and address to be
used for the invitation to the follow-up visit. Patients
could choose to be contacted via sms, e-mail, phone or
post. The envelope also contained a ten page paper-and-
pen questionnaire. The questionnaire did not contain any
ID but a study participant number that was printed on
top. (All questionnaires and CRFs in the study were
marked with the study number only, to make all scanning
and computer analyses anonymous.)
At the clinical visit, the patient was asked to return the
envelope with its contents to the nurse or doctor, who
could also answer questions concerning the study. The
questionnaire, the consent form and the contact form for
the follow-up visit remained in the envelope, and all enve-
lopes were collected and opened by the study staff after
each clinical session. The questionnaires were kept sepa-
rately. The study number was matched to the patients ID
on a list covering names and ID's for each clinical session.
The "code list" was then kept in a separate secure, locked
away register. Consent forms and follow-up visit forms
were stored separately.
Variables
The main variables are the results of the Chlamydia tests
at inclusion and follow-up, related to a history of Chlamy-
dia and to symptoms and signs in female respondents.
The number of partners during the last 12 months and use
of condoms are of particular interest. Some other varia-
bles may be of interest per se. In the questionnaire there
are for example questions about what sources patients
remember receiving information about Chlamydia from,
which may be of interest when planning information
campaigns. Another variable of interest is the patients'
reports on sexual contacts to the counsellor performing
the contact tracing, which may be compared with the
number of contacts they previously reported in the ques-
tionnaire.
Ethics
The research protocol was approved by the local ethical
committee at the Karolinska University Hospital Solna,
Stockholm, Sweden.
Data collection at inclusion
Questionnaire
The questionnaire (Additional file 1) used upon inclusion
was self administered and comprised 10 pages, with mul-
tiple questions with fixed alternative answers. Age, sex andBMC Public Health 2009, 9:198 http://www.biomedcentral.com/1471-2458/9/198
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occupation, partner relations and sexual contact patterns
and condom use was asked for, together with questions
on the history of Chlamydia and Chlamydia testing, and
other STIs. Use of alcohol and drugs was investigated, sex-
ual abuse, use of contraception including emergency con-
traception, and abortion. Terms like "heterosexual",
"homosexual" or "bisexual" were not used, respondents
instead were asked for the gender of sexpartner/sexpart-
ners. In a final question, the respondent was asked to
accept or not accept to turn up for the follow-up visit.
At the development stage of the study the questionnaire
was piloted, and gender-specific feedback and comments
were taken into account when the questionnaire was com-
pleted. Appropriate ways to send an invitation for the fol-
low-up visit were discussed as well.
Laboratory
During the pilot period, a new method of Chlamydia
sampling for females was introduced at the clinic, consist-
ing of self-collected vaginal swabs put into first void urine
and transported in the same plastic tube. Urine testing was
already in use for men. The electronic referrals and test
tubes were labelled "study patient" in order to separate,
freeze and save samples. All samples were and brought
daily to the Dept. of Microbiology at the Karolinska Uni-
versity Hospital.
Ct-analysis was performed by the ProbeTec™ (Becton-
Dickinson [BD] Franklin Lanes, NJ, USA). All samples
positive for Chlamydia were analyzed with a mutant-spe-
cific method, in order to differentiate between nvCT and
wCT [3].
Clinical routines
Patients with symptoms – discharge, dysuria, bleeding in
females, discharge and dysuria in males – were examined
by a physician and promptly treated according to clinical
routines. Patients with a steady partner diagnosed with
Chlamydia, or a referral letter on Chlamydia due to con-
tact tracing. were treated promptly after sampling. Accord-
ing to indication, tests were taken for gonorrhoea,
Mycoplasma genitalium, HIV and syphilis. Doctors were
expected to examine a wet mount, and to conduct direct
microscopy on stained specimens from urethra and cervix.
Treatment of patients with Chlamydia
Treatment for Chlamydia was provided according to the
Swedish routine with doxycycline 100 mg 10, 2 tablets at
the same time the first day, followed by 1 tablet daily. Sex-
ual abstinence during treatment, and participation in con-
tact tracing, belongs to the routine.
All patients with a positive sample for Chlamydia met
with a counsellor for contact tracing with regard to the last
12 months. The appointment was arranged without delay,
and could take place the same day as treatment was pro-
vided. A visit for a "test of cure" with a new Chlamydia test
was scheduled 4 weeks after finishing the treatment. This
test of cure is specific for the study, and not part of the
usual routine. Patients answered a one-page paper-and-
pen questionnaire covering compliance, whether a regular
partner had been treated, whether they had abstained
from having sex with a partner during treatment, and
whether they had had sex with a new partner after finish-
ing treatment.
The counsellors' data collection
Mandatory contact tracing is part of the Swedish routine
for Chlamydia treatment. The contact tracing at Sesam
City is carried out by specially trained counsellors. The
counsellors met with all patients with Chlamydia, and
collected information on sexual partners 12 months back
in time. They contacted all partners, and as far as possible
received information on the results of their Chlamydia
tests, even if tested at other clinics. A few patients did not
show up for contact tracing, and were after reminders
referred to the County Medical Officer in Stockholm
County for further handling. All information was summa-
rized into a log in excel format by two of the counsellors.
CRF
All respondents' medical records were summarized into
clinical report forms, stating reason for visit, genital symp-
toms, if examined by a doctor or not, results from the gen-
ital examination and direct microscopy, whether
treatment was provided before laboratory results, and
results of all laboratory tests, and diagnoses. A CRF cov-
ered one printed page, and was answered by ticking boxes,
filled out retrospectively.
The study log
A log in excel format was kept by the chief investigator for
keeping track on participation rates, results of Chlamydia
tests including nvCT, treatment and follow-up after treat-
ment for Chlamydia, tests of cure, and on further testing
during the intermission between inclusion and late fol-
low-up (interim visits), date for the 6–8 months follow-
up, number of reminders, and the results of the follow-up
Chlamydia tests.
Data collection at follow-up
Patients were invited according to their wishes, i.e.
through sms, e-mail, phone call or letter. They were wel-
come to the clinic within two weeks, at any opening hours
and also early mornings. They were asked to answer a new
paper-and-pen questionnaire and to perform a Chlamy-
dia test. Condoms and Safe-sex information leaflets were
generously distributed. A maximum of three reminders
were used. After six weeks, and due to low follow-up-rates,BMC Public Health 2009, 9:198 http://www.biomedcentral.com/1471-2458/9/198
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we introduced a cinema ticket as a reward for participa-
tion. Treatment, contact tracing and a test-of-cure was per-
formed for all subjects testing positive for Chlamydia
during follow-up, in the same way as during the inclusion
period. A one-page CRF was been completed by the chief
investigator.
The follow-up questionnaire comprised 4 pages (Addi-
tional file 2), and contained questions concerning genital
symptoms related to Chlamydia, sexual behaviour since
the entry visit, and condom use. Two questions addressed
Chlamydia: whether the respondent had been tested at
another clinic since inclusion, and if so the outcome of
the test.
Bias
Patients testing positive for Chlamydia in the study have
been offered a more intensive follow-up than standard
routines in Sweden, as a "test of cure" has been performed
a month after finishing medication. Together with an effi-
cient partner notification provided by the counsellors,
and treatment of partner/partners, the risk for persistent
infection, or reinfections by an untreated partner, should
be minimized. Thus, the study has included an interven-
tion. It is also possible that the probability of drop-out at
follow-up is related to variables of interest. If risk factors
for drop-out are captured at study entry it can be investi-
gated, while changes in lifestyle between entry and follow-
up can not be determined.
Study size
Based on previous research on repeat infections with
Chlamydia [7-15], we estimated that we needed to recruit
a total of 2552 patients to obtain a power of 80% with a
type I error of 5%, assuming that 10% of the respondent
included at entry would be Chlamydia positive, that 10%
of them would be positive again at follow-up, and that 5%
of the Ct-negative respondents at entry would be Ct-posi-
tive at follow-up. This would allow us to study differences
in risk factors between those Ct-positive during both vis-
its, and those first negative and subsequently positive at
follow-up. To cover for an eventual 30% drop-out at fol-
low-up, we decided to distribute 3500 questionnaires.
Participation results
During the inclusion period December 12 2007 to June 2
2008, a total of 5 244 persons aged 20–39 years made vis-
its at the Sesam City Clinic, 3067 (58.5%) men and 2177
(41.5%) women. A total of 3500 questionnaires were dis-
tributed, and 2813 consented to participation. The total
response rate was 53.6% (2813/5244), 46.8% men
(1435/3067) and 63.3% (1378/2177) women.
The Chlamydia test was an essential inclusion criterion.
The frequency of positive tests among all study partici-
pants was 10,9% (306/2813), 12,8% (183/1435) among
males and 8,9% (123/1378) among females.
Discussion
High Chlamydial reinfection rates among teenagers and
young adults are reported from US, UK and Norway. The
relationship between "being infected" and "being infected
again" is estimated only by mathematical models in Swe-
den, indicating high and increasing rates of recurrency
[16]. The present study is the first attempt to investigate
recurrent Chlamydial infections in a clinical setting, and is
now performed as a prospective cohort study at a low
threshold STI-clinic for adults in Stockholm.
A major issue when planning this study was to identify
potential behavioural risk factors for recurrent or repeat
Chlamydial infections, in order to find out if a history of
Chlamydial infection and/or a positive test for Chlamydia
at inclusion would indicate an increased risk for another
positive test at follow-up.
Thorough contact tracing was performed, and "test of
cure", in order to minimize early reinfections by untreated
sexual partners. Identification of nvCT contributes to the
understanding of the occurrence of nvCT investigated ear-
lier at the clinic [24].
Furthermore, the study aims to describe the clinical pres-
entation of Chlamydia, with special regard to women. It is
wellknown that Chlamydia can cause salpingitis, and that
salpingitis (also clinically asymptomatic or "silent") can
cause tubal infertility and ectopic pregnancy [21-23].
Repeat infections increase this risk [25]. The clinical man-
agement of female "repeaters" is a challenge, salpingitis is
a difficult clinical diagnosis, but a positive test for
Chlamydia should include a clinical evaluation of
whether the infection is complicated or uncomplicated,
for prompt treatment.
Recommendations on repeat testing remain to be dis-
cussed.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KE initiated and participated in the design of the project
including clinical routines, and drafted the manuscript.
SK-B participated in the design of the study and per-
formed the initial statistical analyses. MB performed all
the final statistical analyses. MRÖ was responsible for the
microbiological analyses for Chlamydia trachomatis
including the specific analyses for the new variant of
Chlamydia trachomatis, nvCT. IQ and JE performed and
reported all contact tracing. All authors read and approved
the final manuscript.BMC Public Health 2009, 9:198 http://www.biomedcentral.com/1471-2458/9/198
Page 6 of 6
(page number not for citation purposes)
Additional material
Acknowledgements
We would like to thank all the patients who took part in the study, and the 
staff at Sesam City, who were all involved in the survey. Torsten Berglund, 
phD, senior officer att the Swedish National Board of Health and Welfare 
participated in designing the study and questionnaires, and critically read 
the manuscript. Jens Boman, MD County Medical Officer, contributed with 
comments in the planning process and critically read the manuscript.
The project is funded by The Unit for National Co-ordination of HIV/STI 
Prevention at The National Board of Health and Welfare, Stockholm, Swe-
den.
References
1. Statistics from The Swedish Institute for Infectious Disease
Control 2008-12-26   [http://www.smittskyddsinstitutet.se]
2. Edgardh K: [Strong increase of Chlamydia trachomatis. A new
mutant and current sexual habits have had "favourable"
effects for the transmission].  Lakartidningen 2007, 104:3539-42.
Review. Swedish
3. Ripa T, Nilsson PA: A Chlamydia trachomatis strain with a 377-
bp deletion in the cryptic plasmid causing fasle-negative
nucleic acid amplification tests.  Sex Transm Dis 2007, 34:255-56.
4. Soderblom T, Blaxhult A, Fredlund H, Herrmann B: Impact of a
genetic variant of Chlamydia trachomatis on national detec-
tion rates in Sweden.  Sex Transm Infect 2006, 82(3):212-8.
5. Velicko I, Kühlmann-Berenzon S, Blaxhult A: Reasons for the sharp
increase of genital chlamydia infections reported in the first
months of 2007 in Sweden.  Euro Surveill 2007, 12(10):E5-6.
6. European Guideline for the Management of Chlamydial
Infection.  Int Journal of STD and AIDS 2001, 12(suppl 3):30-33.
7. Richey CM, Macaluso M, Hook EW: Determinants of reinfection
with Chlamydia trachomatis.  Sex Transm Dis 1999, 26(1):4-11.
8. Gunn RA, Fitzgerald S, Aral SO: Sexually transmitted disease
clinic clients at risk for subsequent gonorrhoea and chlamy-
dial infections: possible 'core' transmitters.  Sex Transm Dis
2000, 27(6):350-2.
9. Orr DP, Johnston K, Brizendine E, Katz B, Fortenberry JD: Subse-
quent sexually transmitted infection in urban adolescents
and young adults.  Arch Pediatr Adolesc Med 2001, 155(8):947-53.
10. Whittington WL, Kent C, Kissinger P, Oh MK, Fortenberry JD, Hillis
SE, Litchfield B, Bolan GA, St Louis ME, Farley TA, Handsfield HH:
Determinants of persistent and recurrent Chlamydia tra-
chomatis infection in young women: results of a multicenter
cohort study.  Sex Transm Dis 2001, 28(2):117-23.
11. Rietmeijer CA, Van Bemmelen R, Judson FN, Douglas JM Jr: Inci-
dence and repeat infection rates of Chlamydia trachomatis
among male and female patients in an STD clinic: implica-
tions for screening and rescreening.  Sex Transm Dis 2002,
29(2):65-72.
12. Mardh PA, Persson K: Is there a need for rescreening of
patients treated for genital chlamydial infections?  Int J STD
AIDS 2002, 13(6):363-7.
13. Veldhuijzen IK, Van Bergen JE, Gotz HM, Hoebe CJ, Morre SA, Rich-
ardus JH: Reinfections, persistent infections, and new infec-
tions after general population screening for Chlamydia
trachomatis infection in the Netherlands.  Sex Transm Dis 2005,
32(10):599-604.
14. Skjeldestad FE, Marsico MA, Sings HL, Nordbo SA, Storvold G: Inci-
dence and Risk Factors for Genital Chlamydia trachomatis
Infection: a 4-year Prospective Cohort Study.  Sex Transm Dis
2009, 36(5):273-9.
15. Peterman TA, Tian LH, Metcalf CA, Satterwhite CL, Malotte CK,
DeAugustine N, et al.: High incidence of new sexually transmit-
ted infections in the year following a sexually transmitted
infection: a case for rescreening.  Ann Intern Med 2006,
145(8):144.
16. Bengtsson E: Estimating the Infection and Reinfection risk of
Chlamydia trachomatis in Sweden during 1997–2000.   [http://
www2.math.su.se/matstat/reports/serieb/2004/rep10/].
17. Golden MR, Schillinger JA, Markowitz L, St Louis ME: Duration of
Untreated Genital Infections With Chlamydia trachomatis.
A review of the Literature.  Sex Transm Dis 2000, 27(6):329-337.
18. Risser WL, Risser JMH: The incidence of pelvic inflammatory
disease in untreated women infected with Chlamydia traco-
matis: a structured review.  Int J STD & AIDS 2007, 18:727-31.
19. Wallace LA, Scoular A, Hart G, Reid M, Wilson P, Goldberg DJ:
What is the excess of infertility in women after genital
chlamydia infection? A systematic review of the evidence.
Sex Transm Infect 2008, 84(3):171-174.
20. Garnett GP: How much infertility does chlamydia cause?  Edi-
torial, Sex Transm Infect 2008, 84(3):157-8.
21. Low N, Egger M, Sterne JA, Harbord RM, Ibrahim F, Lindblom B, Her-
rmann B: Incidence of severe reproductive tract complica-
tions associated with diagnosed genital chlamydial infection:
the Uppsala Women's Cohort Study.  Sex Transm Infect 2006,
82(3):212-8.
22. Bakken IJ, Skjeldestad FE, Nordbø SA: Chlamydia trachomatis
infections increase the risk for ectopic pregnancy: a popula-
tion-based, nested case-control study.  Sex Transm Dis 2007,
34(3):166-9.
23. Bakken IJ, Skjeldestad FE, Lydersen S, Nordo SA: Births and
Ectopic Pregnancies in a Large Cohort of Women Tested for
Chlamydia trachomatis.  Sex Transm Dis 2007, 34(10):739-43.
24. Marions L, Rotzen Östlund M, Grillner L, Edgardh K, Tiveljung-Lindell
A, Wikström A, Lidbrink P: High occurrence of a new variant of
Chlamydia trachomatis, escaping diagnostic tests, among
STI-clinic patients in Stockholm, Sweden.  Sex Transm Dis 2008,
35(1):61-4.
25. Hillis SD, Owens LM, Marchbanks PA, Amsterdam LE, Mac Kenzie:
Recurrent chlamydial infections increase the risks of hospi-
talization for ectopic pregnancy and pelvis inflammatory dis-
ease.  Am J Obstet Gynecol 1997, 176:103-7.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2458/9/198/pre
pub
Additional file 1
Questionnaire A.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2458-9-198-S1.doc]
Additional file 2
Questionnaire B.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2458-9-198-S2.doc]